- Poster presentation
- Open Access
A case report of a lichenoid eruption in a young lady with Crohn’s disease
© Benhadou and Del Marmol; licensee BioMed Central Ltd. 2012
- Published: 28 November 2012
- Inflammatory Bowel Disease
- Inhibitor Therapy
- Antinuclear Antibody
Crohn’s disease is the most frequent inflammatory bowel disease. The use of the TNFα inhibitors has completely revolutionized the therapeutical management of recalcitrant cases of Crohn’s disease . Unfortunately many side effects have been described in association with the use of the TNFα inhibitors. The development of antinuclear antibodies is frequently described but is not always associated with a pathological condition . The occurrence of lupus like syndrome after initiating the TNFα inhibitors therapy is rare and estimated with a prevalence of 0,5% to 1% . We described a case of a lupus-like syndrome induced by the infliximab in a patient treated for Crohn’s disease.
We report a case of a young woman suffering from Crohn’s disease since 2001. She was treated by infliximab at the dose of 5 mg/kg every 8 weeks since 2009.
Skin biopsies were performed and showed an histological picture of lupus. Six weeks after the withdrawal of the infliximab therapy the skin lesions were completely healed and the anemia was resolved. A diagnosis of a lupus like syndrome induced by the infliximab was retained.
Despite the frequent induction of autoantibody production in patients treated with TNFα inhibitors, the development of lupus like syndrome is uncommon, with a prevalence of 0.5% to 1%. The most cases have been described after the use of infliximab. The skin involvement is rare and the arthralgia are most frequent . A resolution of the symptoms is observed after the discontinuation of the TNFα therapy.
Through the presentation of this case report, we wanted to discuss the role of this autoantibodies and their association with pathological conditions. We wanted also to focuse about the management of the lupus like syndrome induced by the TNFα inhibitors.
- Danese S: Curr Drug Targets. 2010, 11 (2): 136-7. 10.2174/138945010790309911.View ArticlePubMedGoogle Scholar
- Agarwal SK: J Manag Care Pharm. 2011, 17 (9 Suppl B): S14-8.PubMedGoogle Scholar
- De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F: Lupus. 2005, 14 (12): 931-937. 10.1191/0961203305lu2240rr.View ArticlePubMedGoogle Scholar
- Wetter D, Davis M: Mayo Clinic Proceedings. 2009, 84 (11): 979-984.PubMed CentralView ArticlePubMedGoogle Scholar
- Kocharla L, Mongey AB: 1 Lupus. 2009, 18 (2): 169-71. 10.1177/0961203308093922.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.